[{"question": "What age group is covered in the objective tests for diagnosing asthma?", "generated_answer": "The age group covered in the objective tests for diagnosing asthma is children aged 5 to 16.", "true_answer": "Adults, young people, and children aged 5 to 16.", "relevant_docs": ["or there is a significant dela y in obtaining t hem, t he committ ee agr eed it w ould be \nreasonable t o use PEF v ariability as a substitut e rule-in t est. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 44 of\n64 If ast hma is not diagnosed at t his stage, t he only additional in vestigation t hat off ers \nsensitivity wit hout losing significant specificity is a br onchial challenge t est. The \ncommitt ee ar e awar e that t hese t ests are not easily a vailable in man y areas but r easoned \nthat making a positiv e recommendation should encourage ser vices t o impr ove access. \nThey also not ed that met hacholine challenge is mor e sensitiv e than mannit ol but did not \nwant t o fur ther limit t he recommendation. \nChildr en aged 5 t o 16 \nThe committ ee not ed that diagnostic t esting is har der in childr en as t hey ma y find some \ntests difficult t o per form and be unwilling t o have blood t ests. \nA separat e healt h economic model was de veloped f or childr en using childr en-specific \ndiagnostic accuracy data and input s. In childr en, testing f or sensitisation t o house dust \nmite via skin prick t est or finding an ele vated IgE bot h sho wed high sensitivity . Ther efore, \nthe diagnostic strat egy was a rule-in\u2013rule-out appr oach. This pr oved to be t he most cost -\neffectiv e in childr en as it considerably r educed t he pr opor tion of childr en reaching t he last \nstage and needing an e xpensiv e bronchial challenge t est. \nThe committ ee agr eed t hat a cheap and highly specific t est was needed first t o rule in \nasthma. F eNO is a mor e acceptable first t est in childr en than an eosinophil count because \nit avoids t he need t o tak e blood, and because a le vel of 35 ppb or mor e is r easonably \nspecific f or ast hma in t he pr esence of a suggestiv e hist ory. \nThe model suggest ed that a sensitiv e test should come ne xt to rule out ast hma. Ho wever, \nthe committ ee not ed that some childr en w ould not be able t o have a F eNO t est because \nthe equipment is not a vailable in all primar y car e settings, or because a minority ma y not \nbe able t o per form t he necessar y expirat ory manoue vre. The y were also concerned t hat \nan incr easing pr opor tion of childr en wit h ast hma ar e non-at opic and t herefore unlik ely to \nhave a raised F eNO le vel. Ho wever, these childr en ma y sho w bronchodilat or reversibility \n(BDR). It was t herefore agr eed t hat it w ould be appr opriat e to use spir ometr y wit h BDR as \na second t est for those wit hout an ele vated FeNO, or as t he first t est in t hose in whom \nFeNO could not be measur ed. Alt hough t his does not f ollow our optimal model e xactly, \nincluding BDR at t his stage is still cost -effectiv e.", "(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 34 of\n64 and f ormot erol is used f or daily maint enance t herap y and t he relief of sympt oms as \nneeded. The t erms lo w-dose MART and moderat e-dose MART r efer to the dosage of t he \nmaint enance component of MART . People using MART do not normally need a SABA. \nPeak expiratory flo w (P EF) v ariabili ty \nPEF is a measur e of t he maximum speed of e xpiration, generally e xpressed in litr es per \nminut e. PEF v ariability is a measur e of t he extent t o which t his v aries o ver time and can be \nexpressed numerically as amplitude per centage mean. This is calculat ed by subtracting \nthe lo west v alue measur ed each da y from t he highest v alue on t he same da y, and \naveraging t his o ver the number of da ys on which PEF is measur ed \nSkin prick testing \nA test t hat measur es the aller gic response of an individual t o cer tain specific aller gens \nwhen a v ery small amount of t he specific aller gen is intr oduced int o the skin (usually t he \ninner f orearm). \nSpecialist in asthma c are \nA healt hcare professional wit h higher training in r espirat ory medicine and pr oficiency in \nthe management of ast hma. In t he cont ext of t his guideline, t his requir es bot h the relevant \nexper tise and access t o the resour ces t hat enable deliv ery of t he diagnostic and \nmanagement pat hways described in t he recommendations. \nUncontrolled asthma \nA term used when ast hma is ha ving an impact on a person's lif estyle, or is r estricting t heir \nnormal activities, because of sympt oms such as coughing, wheezing, shor tness of br eath \nand chest tightness. Uncontr olled ast hma can include one or bot h of: \n\u2022 any ast hma e xacerbation needing tr eatment wit h oral cor ticost eroids \n\u2022 frequent r egular sympt oms such as: \n\uff0d needing a r eliever inhaler 3 or mor e days per w eek, or \n\uff0d having 1 or mor e night s per w eek when ast hma causes night -time waking. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 35 of\n64 These can be quantified b y questionnair es such as t he Ast hma Contr ol Questionnair e or \nAsthma Contr ol test. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 36 of\n64 Recommenda tions f or research \nThe guideline committ ee has made t he following r ecommendations f or resear ch. \nKey recommenda tions f or research \n1 Medicines f or ini tial manag emen t \nWhat is t he clinical and cost -effectiv eness of r egular 'fix ed-dose' inhaled cor ticost eroid"], "eval_score_GPT4": "4", "eval_feedback_GPT4": "Feedback: The response provided is mostly correct as it accurately identifies children aged 5 to 16 as being within the age group for objective asthma tests. However, it fails to mention adults and young people, which are also included in the reference answer. Therefore, the response is not completely accurate as it omits a significant portion of the age group covered by the objective tests."}, {"question": "What inhaler combination is recommended for symptom relief in newly diagnosed asthma for people aged 12 and over?", "generated_answer": "The combination inhaler of an ICS (budesonide) plus formoterol, a fast onset long-acting beta 2 agonist (LABA), used as needed (as-needed AIR), is recommended for symptom relief in newly diagnosed asthma for people aged 12 and over.", "true_answer": "A low-dose inhaled corticosteroid (ICS)/formoterol combination inhaler.", "relevant_docs": ["people and t he cir cumstances in which t hey might be used . \nHow the r ecommenda tion mig ht affect practice \nDigital inhalers ar e not r ecommended f or routine use in t he NHS, and t his is in line wit h \ncurrent practice. \nReturn t o recommendations \nMedicines f or the ini tial manag emen t of newly \ndiagnose d asthma in pe ople ag ed 12 and o ver \nRecommendations 1 .7.1 and 1 .7.2 \nWhy the c ommi ttee made the r ecommenda tions \nThe committ ee look ed at e vidence comparing 3 tr eatment options in people aged 12 and \nover wit h a new diagnosis of ast hma. These w ere SABA as needed wit h no ICS; r egular \nlow-dose ICS plus SABA as needed; and a combination inhaler of an ICS (budesonide) plus \nformot erol, a f ast onset long-acting beta 2 agonist (L ABA), used as needed (as-needed \nAIR). \nThe most impor tant diff erence betw een t he gr oups was a r eduction in se vere \nexacerbations of ast hma in t he gr oup using as-needed AIR t herap y, and t his applied t o the Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 51 of\n64 comparisons wit h bot h of t he ot her tr eatment options. Ther e were also f ewer \nexacerbations wit h ICS plus SABA t han wit h SABA alone. Apar t from t he diff erence in \nexacerbations, t here were only small diff erences betw een out comes when comparing ICS \nplus SABA as needed wit h as-needed AIR, and t he committ ee did not assess t hese as \nclinically impor tant. Ho wever, the evidence sho wed that use of ICS ( either as-needed AIR \nor regular lo w-dose ICS plus SABA as needed) pr oduced consist ently bett er out comes \nthan SABA alone. \nHealt h economic data sho wed that tr eatment wit h as-needed AIR was cheaper t han \nregular ICS plus SABA as needed. The committ ee therefore concluded t hat combination \ninhalers used as needed should be t he pr eferred tr eatment in newly diagnosed ast hma in \nadult s. Ho wever, there were concerns about t he minority of people wit h ast hma in whom \nthe diagnosis is first made because of an acut e attack. In t hese par ticularly sympt omatic \npeople, t he committ ee agr eed on saf ety gr ounds t hat initial tr eatment should be giv en \nregularly and r ecommended star ting t he lo w-dose MART (maint enance and r eliever \ntherap y) regimen. \nHow the r ecommenda tions mig ht affect practice \nMost people aged 12 and o ver wit h newly diagnosed ast hma ar e curr ently treated wit h \neither a SABA alone or wit h regular ICS plus SABA as needed. The new r ecommendations \nrepresent a significant change in practice. The use of combination inhalers is mor e \nexpensiv e than SABA alone, but cheaper t han r egular ICS plus SABA as needed. Ther efore, \nthe cost impact will v ary depending on t he pr edominant f orm of tr eatment in each general", "relies on using MART wit h incr easing dose of r egular ICS/f ormot erol, depending on \nresponse t o treatment. This is a diff erent strat egy fr om t hat r ecommended b y previous \nguidelines (NICE and BTS/SIGN) and man y people will be on tr eatment t hat is not par t of \nthis new pat hway. The committ ee recognised t hat t his will cause a pr oblem f or these \npeople when t heir ast hma is not contr olled. The y therefore discussed and agr eed ho w \ntreatment should be changed in t hese cir cumstances. The y not ed that t he general advice \nabout checking inhaler t echnique, adher ence, et c. (see recommendation 1 .6.1 in t he \nsection on principles of pharmacological tr eatment ) bef ore escalating tr eatment still \napplies her e. The r ecommendations ar e not based on a specific e vidence sear ch, but t he \ncommitt ee not ed that people in t he MART studies r eview ed for recommendations 1 .7.3 to \n1.7.6 (see t he section on medicine combination and sequencing in people aged 12 and \nover) were taking some f orm of non-MART t herap y bef ore study entr y and t hat t he \nimprovement sho wn in comparison t o bot h baseline and t o the contr ol treatment s suppor t \nthe swit ch to MART . \nHow the r ecommenda tions mig ht affect practice \nThe r ecommendations will r esult in mor e people being swit ched t o MART t han t o other \ntreatment options, but MART is used at pr esent, and t he change should not be disruptiv e. \nReturn t o recommendations \nMedicines f or ini tial manag emen t in childr en ag ed \n5 to 11 \nRecommendation 1 .8.1 Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 55 of\n64 Why the c ommi ttee made the r ecommenda tion \nEvidence f or childr en aged 5 t o 11 sho wed that r egular paediatric lo w-dose ICS plus SABA \nas needed was superior t o SABA alone, par ticularly in r educing e xacerbations. Using \nregular ICS did not cause mor e side eff ects and was not associat ed wit h greater adr enal \nsuppr ession. Ther e was no e vidence f or ICS/f ormot erol combination inhalers used as \nneeded in t his age gr oup. The committ ee therefore recommended r egular paediatric lo w-\ndose ICS as t he pr eferred tr eatment option f or childr en aged 5 t o 11. However, in view of \nthe evidence suppor ting t he use of ICS/L ABA as needed combination inhalers in adult s, \nthey made a resear ch recommendation t o test t he benefit s of t his combination in childr en. \nHow the r ecommenda tion mig ht affect practice \nThe r ecommendation f or treatment of newly diagnosed ast hma in childr en is in line wit h \ncurrent practice. \nReturn t o recommendations \nMedicine c ombina tion and se quencing in childr en \naged 5 to 11 \nRecommendations 1 .8.2 to 1.8.7 \nWhy the c ommi ttee made the r ecommenda tions"], "eval_score_GPT4": "5", "eval_feedback_GPT4": "The response provided is completely correct, accurate, and factual. It specifies the use of an ICS (budesonide) and formoterol, which is a fast-acting LABA, for symptom relief in newly diagnosed asthma for people aged 12 and over. This aligns with the reference answer, which mentions a low-dose ICS/formoterol combination inhaler. The response even adds that it is used as needed, which is a relevant detail for asthma management."}, {"question": "How long should a leukotriene receptor antagonist (LTRA) be given for a trial period in children under 5 with suspected uncontrolled asthma?", "generated_answer": "The context does not provide information on the trial period for a leukotriene receptor antagonist (LTRA) in children under 5 with suspected uncontrolled asthma. However, it does mention that for children aged 5 to 11, the trial period for an LTRA should be 8 to 12 weeks (unless there are side effects), as stated in section 1.8.4.", "true_answer": "8 to 12 weeks.", "relevant_docs": ["1.8.1 Offer a twice-daily paediatric lo w-dose inhaled cor ticost eroid (ICS), wit h a shor t-\nacting beta 2 agonist (SABA) as needed, as initial tr eatment f or childr en aged 5 t o \n11 years wit h newly diagnosed ast hma. [BTS/NICE/SIGN 202 4] \nFor a shor t explanation of wh y the committ ee made t his recommendation and ho w it \nmight aff ect practice, see t he rationale and impact section on medicines f or initial \nmanagement in childr en aged 5 t o 11. \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview  P: \ndrug classes f or initial ast hma management . \nMedicine c ombina tion and se quencing in childr en ag ed 5 to 11 \nMART pat hwa y \n1.8.2 Consider paediatric lo w-dose MART ( maint enance and r eliever therap y) for \nchildr en wit h ast hma t hat is not contr olled on paediatric lo w-dose ICS plus SABA \nas needed, as long as t hey are assessed t o have the ability t o manage a MART \nregimen. [BTS/NICE/SIGN 202 4] \nIn No vember 202 4, no ast hma inhalers w ere licensed f or MART in childr en under \n12, so t his use w ould be off -label. The curr ent e vidence suppor ting t he use of \nMART in childr en aged 5 t o 11 is based on t he use of a dr y powder inhaler . See \nNICE's inf ormation on pr escribing medicines  or SIGN's inf ormation on pr escribing \nlicensed medicines outwit h their mark eting aut horisation . Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 23 of\n64 1.8.3 Consider incr easing t o paediatric moderat e-dose MART if ast hma is not \ncontr olled on paediatric lo w-dose MART . [BTS/NICE/SIGN 202 4] \nCon ventional pat hwa y \n1.8.4 Consider adding a leukotriene r ecept or antagonist  (LTRA) t o twice daily \npaediatric lo w-dose ICS plus SABA as needed when a child has uncontr olled \nasthma and is assessed as unable t o manage t he MART r egimen. G ive the LTRA \nfor a trial period of 8 t o 12 w eeks (unless t here are side eff ects), then st op it if it \nis ineff ectiv e. [BTS/NICE/SIGN 202 4] \nNovember 202 4: Follow the MHRA saf ety advice on t he risk of neur opsy chiatric \nreactions in people taking mont elukast . \n1.8.5 Offer a twice daily paediatric lo w-dose ICS/L ABA ( long-acting beta 2 agonist ) \ncombination inhaler plus SABA as needed t o childr en assessed as unable t o \nmanage t he MART r egimen if t heir ast hma is not contr olled on paediatric lo w-\ndose ICS plus SABA as needed (wit h or wit hout an L TRA depending on pr evious \nresponse). [BTS/NICE/SIGN 202 4] \n1.8.6 Offer a twice daily paediatric moderat e-dose ICS/L ABA inhaler plus SABA as \nneeded t o childr en wit h ast hma t hat is not contr olled on paediatric lo w-dose ICS/\nLABA plus SABA as needed (wit h or wit hout an L TRA depending on pr evious \nresponse). [BTS/NICE/SIGN 202 4] \nAll childr en aged 5 t o 11", "asthma in adult s, young people and childr en aged 5 t o 16 wit h a hist ory suggestiv e of \nasthma. \nFull details of t he evidence and t he committ ee's discussion ar e in: \n\u2022 evidence r eview  A: diagnostic t est accuracy of spir ometr y in people suspect ed of \nasthma \n\u2022 evidence r eview  B: diagnostic t est accuracy f or br onchodilat or reversibility in \npeople suspect ed of ast hma \n\u2022 evidence r eview  C: diagnostic t est accuracy of peak e xpirat ory flow variability f or \nthe diagnosis of ast hma \n\u2022 evidence r eview  D: accuracy of skin prick t est in childr en for the diagnosis of \nasthma \n\u2022 evidence r eview E: diagnostic t est accuracy of IgE in childr en \n\u2022 evidence r eview  F: diagnostic accuracy of fractional e xhaled nitric o xide (F eNO) \nmeasur es \n\u2022 evidence r eview  G: diagnostic accuracy of eosinophil blood count measur es in t he \ndiagnosis of ast hma \n\u2022 evidence r eview  H: br onchial challenge wit h histamine and met hacholine f or the \ndiagnosis of ast hma \n\u2022 evidence r eview  I: bronchial challenge t est wit h mannit ol \n\u2022 evidence r eview  J: bronchial challenge t esting in r esponse t o exercise f or the \ndiagnosis of ast hma \n\u2022 evidence r eview  K: diagnostic accuracy of combination of t ests. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 39 of\n64 4 Inhaler s \nCan digital inhaler monit ors cost -effectiv ely impr ove adher ence t o preventer inhalers f or \npeople wit h ast hma? Does t his impr ove ast hma contr ol and who w ould benefit most fr om \nthis int ervention? [BTS/NICE/SIGN 202 4] \nFor a shor t explanation of wh y the committ ee made t his recommendation f or \nresear ch, see t he rationale and impact section on digital inhalers . \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview  R: \nsmar t inhalers . \n5 Monitoring inhaler te chnique \nWhat is t he curr ent fr equency and t he curr ent met hod being used t o check t he inhaler \ntechnique of people wit h ast hma? What is t he optimal fr equency and t he best met hod of \nchecking inhaler t echnique t o impr ove clinical out comes f or people wit h ast hma? [NICE \n2017] \n6 Monitoring asthma c ontrol using telehe althcare \nWhat is t he long-t erm (mor e than 12 mont hs) clinical and cost -effectiv eness of using \ntelehealt hcare as a means t o monit or ast hma contr ol in adult s, young people and childr en? \nMethods of t elehealt hcare can include t elephone int erview (wit h healt hcare professional \ninvolvement) and int ernet or smar tphone-based monit oring suppor t (no healt hcare \nprofessional in volvement). [NICE 2017] \n7 De creasing p harmac ological treatmen t \nIn adult s, young people and childr en wit h well-contr olled ast hma, what ar e the objectiv e"], "eval_score_GPT4": "2", "eval_feedback_GPT4": "The response does not directly answer the question regarding the trial period for LTRA in children under 5 with suspected uncontrolled asthma. Instead, it provides information about the trial period for children aged 5 to 11, which was not asked for. The response does not state the correct trial period of 8 to 12 weeks for the specified age group under 5. Therefore, the response is mostly incorrect and not factual as per the given instruction."}, {"question": "Why are digital inhalers not recommended for routine use in asthma management?", "generated_answer": "According to the context, digital inhalers are not recommended for routine use in asthma management because the committee concluded that they are not a cost-effective option for routine use in asthma. However, they are potentially valuable in selected people with asthma, for example, those in whom the need for biologic therapy is being considered and there is a need to confirm good adherence.", "true_answer": "Digital inhalers are not recommended for routine use in asthma management because they are not cost-effective and did not result in significant improvement in asthma control measures.", "relevant_docs": ["people wit h ast hma. The y therefore recommended t hat SABA alone should not be used in \npeople wit h a diagnosis of ast hma. \nThe pr evious NICE and BTS/SIGN guidelines had r ecommended a number of actions which \nshould be tak en bef ore incr easing tr eatment, and t he committ ee agr eed b y consensus t hat \na FeNO check should also be done as long as t he equipment is a vailable t o do t his. \nHow the r ecommenda tions mig ht affect practice \nThe pr escription of SABA alone has been commonplace, alt hough t his is becoming less so \nbecause of t he publicity ar ound ast hma deat hs. The r ecommendation will r educe it s use \nfurther. The r eplacement t herapies in adult s and childr en ar e mor e expensiv e, but t hey \nshould pr oduce clinical benefit s and cost sa vings t hrough a r eduction in e xacerbations. \nReturn t o recommendations \nDigital inhaler s \nRecommendation 1 .6.10 \nWhy the c ommi ttee made the r ecommenda tion \nThe committ ee look ed at e vidence comparing t he use of digital smar t inhalers wit h usual \ncare and wit h digital inhalers wit h the feedback utility swit ched off . The trials included \nboth childr en and adult s wit h ast hma, and a v ariety of types of inhaler . The e vidence Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 50 of\n64 showed impr ovement in adher ence t o treatment wit h digital inhalers, but t his did not r esult \nin significant impr ovement in measur es of ast hma contr ol. In addition, t here was an \nunexplained incr ease in hospital admissions among people using digital inhalers when \ncompar ed wit h usual car e. The par ticipant s in t he contributing trials v aried considerably in \nterms of baseline adher ence and ast hma contr ol, and benefit was generally mor e likely in \nthe studies of people wit h poor er baseline v alues. \nDigital inhalers ar e mor e expensiv e than con ventional de vices, par tly because of t he \ndevice it self and par tly because of t he set -up and monit oring r equir ement s. The \ncommitt ee concluded t hat digital inhalers ar e not a cost -effectiv e option f or routine use in \nasthma. Ho wever, they are pot entially v aluable in select ed people wit h ast hma, f or \nexample t hose in whom t he need f or biologic t herap y is being consider ed and t here is a \nneed t o confirm good adher ence. Further r esear ch is needed t o identify mor e precisely t he \npeople and t he cir cumstances in which t hey might be used . \nHow the r ecommenda tion mig ht affect practice \nDigital inhalers ar e not r ecommended f or routine use in t he NHS, and t his is in line wit h \ncurrent practice. \nReturn t o recommendations \nMedicines f or the ini tial manag emen t of newly \ndiagnose d asthma in pe ople ag ed 12 and o ver \nRecommendations 1 .7.1 and 1 .7.2 \nWhy the c ommi ttee made the r ecommenda tions", "(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 34 of\n64 and f ormot erol is used f or daily maint enance t herap y and t he relief of sympt oms as \nneeded. The t erms lo w-dose MART and moderat e-dose MART r efer to the dosage of t he \nmaint enance component of MART . People using MART do not normally need a SABA. \nPeak expiratory flo w (P EF) v ariabili ty \nPEF is a measur e of t he maximum speed of e xpiration, generally e xpressed in litr es per \nminut e. PEF v ariability is a measur e of t he extent t o which t his v aries o ver time and can be \nexpressed numerically as amplitude per centage mean. This is calculat ed by subtracting \nthe lo west v alue measur ed each da y from t he highest v alue on t he same da y, and \naveraging t his o ver the number of da ys on which PEF is measur ed \nSkin prick testing \nA test t hat measur es the aller gic response of an individual t o cer tain specific aller gens \nwhen a v ery small amount of t he specific aller gen is intr oduced int o the skin (usually t he \ninner f orearm). \nSpecialist in asthma c are \nA healt hcare professional wit h higher training in r espirat ory medicine and pr oficiency in \nthe management of ast hma. In t he cont ext of t his guideline, t his requir es bot h the relevant \nexper tise and access t o the resour ces t hat enable deliv ery of t he diagnostic and \nmanagement pat hways described in t he recommendations. \nUncontrolled asthma \nA term used when ast hma is ha ving an impact on a person's lif estyle, or is r estricting t heir \nnormal activities, because of sympt oms such as coughing, wheezing, shor tness of br eath \nand chest tightness. Uncontr olled ast hma can include one or bot h of: \n\u2022 any ast hma e xacerbation needing tr eatment wit h oral cor ticost eroids \n\u2022 frequent r egular sympt oms such as: \n\uff0d needing a r eliever inhaler 3 or mor e days per w eek, or \n\uff0d having 1 or mor e night s per w eek when ast hma causes night -time waking. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 35 of\n64 These can be quantified b y questionnair es such as t he Ast hma Contr ol Questionnair e or \nAsthma Contr ol test. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 36 of\n64 Recommenda tions f or research \nThe guideline committ ee has made t he following r ecommendations f or resear ch. \nKey recommenda tions f or research \n1 Medicines f or ini tial manag emen t \nWhat is t he clinical and cost -effectiv eness of r egular 'fix ed-dose' inhaled cor ticost eroid"], "eval_score_GPT4": "4", "eval_feedback_GPT4": "Feedback: The response provided aligns well with the reference answer, stating that digital inhalers are not recommended for routine use in asthma management due to cost-effectiveness issues. Additionally, the response adds that digital inhalers may be valuable for selected individuals, which is not contradictory to the reference answer but provides further context. This additional information does not detract from the accuracy but rather enhances the understanding of when digital inhalers might be considered. Therefore, the response is mostly correct, accurate, and factual."}, {"question": "What is the recommended treatment for a child whose asthma is uncontrolled on regular low-dose ICS?", "generated_answer": "According to the context, the recommended treatment for a child whose asthma is uncontrolled on regular low-dose ICS would be adding an LTRA (Leukotriene Modulator) or adding a LABA (Long-acting Beta-agonist) or increasing the maintenance ICS dose. However, the evidence did not show one option to be clearly superior in terms of benefits or adverse events.", "true_answer": "Paediatric low-dose MART is the best treatment.", "relevant_docs": ["(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 36 of\n64 Recommenda tions f or research \nThe guideline committ ee has made t he following r ecommendations f or resear ch. \nKey recommenda tions f or research \n1 Medicines f or ini tial manag emen t \nWhat is t he clinical and cost -effectiv eness of r egular 'fix ed-dose' inhaled cor ticost eroid \n(ICS) r egimens (using SABA [shor t-acting beta 2 agonist] as a r eliever) compar ed wit h 'as-\nneeded' strat egies (f or example ICS/f ormot erol) as t he initial standar d treatment f or \nasthma in childr en aged 5 t o 11 y ears? [BTS/NICE/SIGN 202 4] \nFor a shor t explanation of wh y the committ ee made t his recommendation f or \nresear ch, see t he rationale and impact section on medicines f or initial management in \nchildr en aged 5 t o 11. \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview  P: \ndrug classes f or initial ast hma management . \n2 Medicine c ombina tion and se quencing \nWhat is t he best st ep-up tr eatment f or people whose ast hma is not contr olled on a \ncombination inhaler of ICS plus f ormot erol used as needed? [BTS/NICE/SIGN 202 4] \nFor a shor t explanation of wh y the committ ee made t his recommendation f or \nresear ch, see t he rationale and impact section on medicine combination and \nsequencing in people aged 12 and o ver. \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview  Q: \ndrug combinations and sequencing f or ast hma management . Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 37 of\n64 3 Diagnostic pa thways \nWhat is t he cost -effectiv eness and f easibility of t he pr oposed BTS/NICE/SIGN diagnostic \npathways for ast hma in childr en and y oung people aged 5 and o ver and in adult s aged 17 \nand o ver? [BTS/NICE/SIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 38 of\n64 For a shor t explanation of wh y the committ ee made t his recommendation f or \nresear ch, see t he rationale and impact section on objectiv e tests for diagnosing \nasthma in adult s, young people and childr en aged 5 t o 16 wit h a hist ory suggestiv e of \nasthma. \nFull details of t he evidence and t he committ ee's discussion ar e in: \n\u2022 evidence r eview  A: diagnostic t est accuracy of spir ometr y in people suspect ed of \nasthma \n\u2022 evidence r eview  B: diagnostic t est accuracy f or br onchodilat or reversibility in \npeople suspect ed of ast hma \n\u2022 evidence r eview  C: diagnostic t est accuracy of peak e xpirat ory flow variability f or", "willing t o prescribe it. \nFor childr en whose ast hma is uncontr olled on r egular paediatric lo w-dose ICS and who ar e \nunable t o manage t he MART r egimen, t he choice of tr eatment w ould be betw een adding \nan LTRA, adding a L ABA, or incr easing t he maint enance ICS dose. The e vidence did not \nshow one option t o be clearly superior in t erms of benefit s or adv erse e vents, alt hough t he \ncommitt ee not ed that pr escribers should warn people of possible neur opsy chiatric \nproblems wit h mont elukast. (See t he MHRA drug saf ety updat e on t he risk of \nneuropsy chiatric r eactions in people taking mont elukast .) The committ ee agr eed t hat \nadding an L TRA t o the regular ICS tr eatment should be tried first as t his limit s the child's \nexposur e to ICS and is less e xpensiv e than using ICS/L ABA inhalers. The y used t heir \nknowledge and e xper tise t o recommend fur ther st eps if ast hma contr ol is not achie ved. \nThe committ ee also agr eed t hat if ast hma contr ol was not achie ved on a r egular moderat e \ndose of ICS ( either as paediatric moderat e-dose MART or r egular paediatric moderat e-\ndose ICS/L ABA plus SABA as needed), an opinion should be sought fr om a specialist in \nasthma car e bef ore escalating t o a paediatric high-dose ICS r egimen. \nHow the r ecommenda tions mig ht affect practice \nThe r ecommendation f or MART as t he pr eferred st ep-up tr eatment is new , but t his is not \nintended f or childr en who ar e stable on curr ent t herap y, and intr oducing it should not be \ndisruptiv e. It will bring adv antages in t erms of r educing ast hma attacks. In addition, MART \nwill not be suitable f or some childr en, and t he recommendations f or treatment in t his gr oup \nare in line wit h curr ent practice. Ov erall, t he changes ar e modest and will be cost -effectiv e \nfor the NHS. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 57 of\n64 Return t o recommendations \nPharmac ological manag emen t in childr en under 5 \nRecommendations 1 .9.1 to 1.9.6 \nWhy the c ommi ttee made the r ecommenda tions \nEvidence was a vailable f or 5 tr eatment options: SABA alone used as needed; r egular ICS \nplus SABA as needed; SABA/ICS combination inhaler used as needed; r egular SABA/ICS \ncombination inhaler; and r egular mont elukast. The e vidence did not encompass all \npossible comparisons of t he 5 options, but o verall, t hose t hat included t he use of an ICS \nclearly sho wed gr eater benefit s than t hose wit hout an ICS, and r egular ICS ( either ICS \nalone or ICS/SABA) was superior t o intermitt ent ICS/SABA. The most impor tant benefit s of \nregular ICS w ere seen in r educing e xacerbations or hospital admissions. Ther e was no \nadvantage t o using r egular ICS/SABA inst ead of r egular ICS alone."], "eval_score_GPT4": "3", "eval_feedback_GPT4": "The response provided offers a variety of treatment options for a child whose asthma is uncontrolled on regular low-dose ICS, including adding an LTRA, a LABA, or increasing the ICS dose. This aligns with general asthma management strategies but does not specifically mention paediatric low-dose MART, which is indicated as the best treatment in the reference answer. The response is somewhat correct as it does suggest appropriate alternatives for asthma management, but it lacks the precision and specificity of the reference answer in identifying the best treatment."}, {"question": "What FeNO level indicates asthma diagnosis in adults with a history suggestive of asthma?", "generated_answer": "According to the context, a FeNO level of 50 ppb or more indicates asthma diagnosis in adults with a history suggestive of asthma.", "true_answer": "50 ppb or more.", "relevant_docs": ["young pe ople and childr en ag ed 5 to 16 wi th a \nhistor y sug gestive of asthma \nAdults \nSee also algorit hm A f or a summar y of objectiv e tests for diagnosing ast hma in adult s and \nyoung people (aged o ver 16 y ears) wit h a hist ory suggesting ast hma. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 10 of\n64 1.2.1 Measur e the blood eosinophil count  or fractional e xhaled nitric o xide (F eNO) le vel \nin adult s wit h a hist ory suggestiv e of ast hma. Diagnose ast hma if t he eosinophil \ncount is abo ve the laborat ory reference range or t he FeNO le vel is 50 ppb or \nmore. [BTS/NICE/SIGN 202 4] \n1.2.2 If ast hma is not confirmed b y eosinophil count or F eNO le vel, measur e \nbronchodilat or reversibility  (BDR) wit h spir ometr y. Diagnose ast hma if t he FEV1 \nincrease is 12% or mor e and 200 ml or mor e from t he pr e-bronchodilat or \nmeasur ement ( or if t he FEV 1 increase is 10% or mor e of t he pr edict ed normal \nFEV1). [BTS/NICE/SIGN 202 4] \n1.2.3 If spir ometr y is not a vailable or it is dela yed, measur e peak e xpirat ory flow (PEF) \ntwice daily f or 2 w eeks. Diagnose ast hma if PEF v ariability ( expressed as \namplitude per centage mean) is 20% or mor e. [BTS/NICE/SIGN 202 4] \n1.2.4 If ast hma is not confirmed b y eosinophil count, F eNO, BDR or PEF v ariability but \nstill suspect ed on clinical gr ounds, r efer for consideration of a bronchial challenge \ntest. Diagnose ast hma if bronchial h yper-responsiv eness  is present. [BTS/NICE/\nSIGN 202 4] \nChildr en ag ed 5 to 16 \nSee also algorit hm B f or a summar y of objectiv e tests for diagnosing ast hma in childr en \naged 5 t o 16 wit h a hist ory suggesting ast hma. \n1.2.5 Measur e the FeNO le vel in childr en wit h a hist ory suggestiv e of ast hma. Diagnose \nasthma if t he FeNO le vel is 35  ppb or mor e. [BTS/NICE/SIGN 202 4] \n1.2.6 If the FeNO level is not raised, or if F eNO t esting is not a vailable, measur e BDR \nwith spir ometr y. Diagnose ast hma if t he FEV 1 increase is 12% or mor e from \nbaseline ( or if t he FEV 1 increase is 10% or mor e of t he pr edict ed normal FEV 1). \n[BTS/NICE/SIGN 202 4] \n1.2.7 If spir ometr y is not a vailable or it is dela yed, measur e PEF twice daily f or 2 w eeks. \nDiagnose ast hma if PEF v ariability ( expressed as amplitude per centage mean) is \n20% or mor e. [BTS/NICE/SIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 11 of\n64 1.2.8 If asthma is not confirmed b y FeNO, BDR or PEF v ariability but still suspect ed on \nclinical gr ounds, eit her per form skin prick t esting  to house dust mit e or measur e \ntotal IgE le vel and blood eosinophil count.", "(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 34 of\n64 and f ormot erol is used f or daily maint enance t herap y and t he relief of sympt oms as \nneeded. The t erms lo w-dose MART and moderat e-dose MART r efer to the dosage of t he \nmaint enance component of MART . People using MART do not normally need a SABA. \nPeak expiratory flo w (P EF) v ariabili ty \nPEF is a measur e of t he maximum speed of e xpiration, generally e xpressed in litr es per \nminut e. PEF v ariability is a measur e of t he extent t o which t his v aries o ver time and can be \nexpressed numerically as amplitude per centage mean. This is calculat ed by subtracting \nthe lo west v alue measur ed each da y from t he highest v alue on t he same da y, and \naveraging t his o ver the number of da ys on which PEF is measur ed \nSkin prick testing \nA test t hat measur es the aller gic response of an individual t o cer tain specific aller gens \nwhen a v ery small amount of t he specific aller gen is intr oduced int o the skin (usually t he \ninner f orearm). \nSpecialist in asthma c are \nA healt hcare professional wit h higher training in r espirat ory medicine and pr oficiency in \nthe management of ast hma. In t he cont ext of t his guideline, t his requir es bot h the relevant \nexper tise and access t o the resour ces t hat enable deliv ery of t he diagnostic and \nmanagement pat hways described in t he recommendations. \nUncontrolled asthma \nA term used when ast hma is ha ving an impact on a person's lif estyle, or is r estricting t heir \nnormal activities, because of sympt oms such as coughing, wheezing, shor tness of br eath \nand chest tightness. Uncontr olled ast hma can include one or bot h of: \n\u2022 any ast hma e xacerbation needing tr eatment wit h oral cor ticost eroids \n\u2022 frequent r egular sympt oms such as: \n\uff0d needing a r eliever inhaler 3 or mor e days per w eek, or \n\uff0d having 1 or mor e night s per w eek when ast hma causes night -time waking. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 35 of\n64 These can be quantified b y questionnair es such as t he Ast hma Contr ol Questionnair e or \nAsthma Contr ol test. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 36 of\n64 Recommenda tions f or research \nThe guideline committ ee has made t he following r ecommendations f or resear ch. \nKey recommenda tions f or research \n1 Medicines f or ini tial manag emen t \nWhat is t he clinical and cost -effectiv eness of r egular 'fix ed-dose' inhaled cor ticost eroid"], "eval_score_GPT4": "5", "eval_feedback_GPT4": "The response provided is completely correct, accurate, and factual. It aligns perfectly with the reference answer, which states that a FeNO level of 50 ppb or more indicates asthma diagnosis in adults with a history suggestive of asthma. The response includes the same threshold value for FeNO levels as the reference answer, ensuring that the information given is precise and directly addresses the question asked. There is no deviation from the facts presented in the reference answer, and the response is presented with clarity."}, {"question": "What should people with confirmed asthma currently using only a short-acting beta 2 agonist (SABA) be changed to?", "generated_answer": "According to the context, people with asthma that is not controlled on a short-acting beta 2 agonist (SABA) should be changed to a moderate-dose ICS (inhaler) plus SABA as needed.", "true_answer": "A low-dose ICS/formoterol combination inhaler used as needed (as-needed AIR therapy).", "relevant_docs": ["plus SABA as needed Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 21 of\n64 \u2022 regular lo w-dose ICS and supplementar y therap y (LTRA) plus SABA as \nneeded. \n\u2022 regular lo w-dose ICS/L ABA combination inhaler and supplementar y therap y \n(LTRA) plus SABA as needed. [BTS/NICE/SIGN 202 4] \n1.7.9 Consider changing tr eatment t o moderat e-dose MART f or people wit h ast hma \nthat is not contr olled on: \n\u2022 regular moderat e-dose ICS plus SABA as needed \n\u2022 regular moderat e-dose ICS/L ABA combination inhaler plus SABA as needed \n\u2022 regular moderat e-dose ICS and supplementar y therap y (LTRA or L AMA, or \nboth) plus SABA as needed \n\u2022 regular moderat e-dose ICS/L ABA combination inhaler and supplementar y \ntherap y (LTRA or L AMA, or bot h) plus SABA as needed. [BTS/NICE/SIGN \n202 4] \n1.7.10 When changing fr om lo w- or moderat e-dose ICS ( or ICS/L ABA combination \ninhaler) plus supplementar y therap y to MART , consider whet her t o stop or \ncontinue t he supplementar y therap y based on t he degr ee of benefit achie ved \nwhen first intr oduced. [BTS/NICE/SIGN 202 4] \n1.7.11 Refer people wit h ast hma t hat is not contr olled on tr eatment containing a high \ndose of ICS t o a specialist in ast hma car e. [BTS/NICE/SIGN 202 4] \nFor a shor t explanation of wh y the committ ee made t hese r ecommendations and ho w \nthey might aff ect practice, see t he rationale and impact section on transf erring people \naged 12 and o ver from ot her tr eatment pat hways. \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview  P: \ndrug classes f or initial ast hma management and evidence r eview Q: drug \ncombinations and sequencing f or ast hma management . \n1.8 P harmac ological manag emen t in childr en ag ed 5 Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 22 of\n64 to 11 \nFor guidance on doses on inhaled cor ticost eroids see inhaled cor ticost eroid doses f or the \nBTS, NICE and SIGN ast hma guideline . \nSee also algorit hm D f or a summar y of t he pharmacological management of ast hma in \nchildr en aged 5 t o 11 y ears. \nInitial manag emen t in childr en ag ed 5 to 11 \n1.8.1 Offer a twice-daily paediatric lo w-dose inhaled cor ticost eroid (ICS), wit h a shor t-\nacting beta 2 agonist (SABA) as needed, as initial tr eatment f or childr en aged 5 t o \n11 years wit h newly diagnosed ast hma. [BTS/NICE/SIGN 202 4] \nFor a shor t explanation of wh y the committ ee made t his recommendation and ho w it \nmight aff ect practice, see t he rationale and impact section on medicines f or initial \nmanagement in childr en aged 5 t o 11.", "(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 36 of\n64 Recommenda tions f or research \nThe guideline committ ee has made t he following r ecommendations f or resear ch. \nKey recommenda tions f or research \n1 Medicines f or ini tial manag emen t \nWhat is t he clinical and cost -effectiv eness of r egular 'fix ed-dose' inhaled cor ticost eroid \n(ICS) r egimens (using SABA [shor t-acting beta 2 agonist] as a r eliever) compar ed wit h 'as-\nneeded' strat egies (f or example ICS/f ormot erol) as t he initial standar d treatment f or \nasthma in childr en aged 5 t o 11 y ears? [BTS/NICE/SIGN 202 4] \nFor a shor t explanation of wh y the committ ee made t his recommendation f or \nresear ch, see t he rationale and impact section on medicines f or initial management in \nchildr en aged 5 t o 11. \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview  P: \ndrug classes f or initial ast hma management . \n2 Medicine c ombina tion and se quencing \nWhat is t he best st ep-up tr eatment f or people whose ast hma is not contr olled on a \ncombination inhaler of ICS plus f ormot erol used as needed? [BTS/NICE/SIGN 202 4] \nFor a shor t explanation of wh y the committ ee made t his recommendation f or \nresear ch, see t he rationale and impact section on medicine combination and \nsequencing in people aged 12 and o ver. \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview  Q: \ndrug combinations and sequencing f or ast hma management . Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 37 of\n64 3 Diagnostic pa thways \nWhat is t he cost -effectiv eness and f easibility of t he pr oposed BTS/NICE/SIGN diagnostic \npathways for ast hma in childr en and y oung people aged 5 and o ver and in adult s aged 17 \nand o ver? [BTS/NICE/SIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 38 of\n64 For a shor t explanation of wh y the committ ee made t his recommendation f or \nresear ch, see t he rationale and impact section on objectiv e tests for diagnosing \nasthma in adult s, young people and childr en aged 5 t o 16 wit h a hist ory suggestiv e of \nasthma. \nFull details of t he evidence and t he committ ee's discussion ar e in: \n\u2022 evidence r eview  A: diagnostic t est accuracy of spir ometr y in people suspect ed of \nasthma \n\u2022 evidence r eview  B: diagnostic t est accuracy f or br onchodilat or reversibility in \npeople suspect ed of ast hma \n\u2022 evidence r eview  C: diagnostic t est accuracy of peak e xpirat ory flow variability f or"], "eval_score_GPT4": "3", "eval_feedback_GPT4": "The response provided suggests a change to a moderate-dose ICS plus SABA as needed for asthma not controlled by SABA alone. While this recommendation aligns with the general step-up approach in asthma management, it does not specifically mention the use of a low-dose ICS/formoterol combination inhaler as needed, which is the reference answer. The response is somewhat correct in that it does recommend a combination therapy involving an ICS, but it is not accurate in terms of the specific medication combination and dosing strategy (low-dose ICS/formoterol) that is suggested in the reference answer. Therefore, the response is somewhat correct, accurate, and factual, but not completely so."}, {"question": "What type of sphygmomanometers have replaced mercury-based sphygmomanometers according to recent studies?", "generated_answer": "The context does not mention the type of sphygmomanometers that have replaced mercury-based sphygmomanometers. The context is related to asthma management guidelines and does not discuss blood pressure measurement or sphygmomanometers.", "true_answer": "Electronic sphygmomanometers.", "relevant_docs": ["Who is it f or? .......................................................................................................................................... 4 \nRecommendations ...................................................................................................................... 5 \n1.1 Measuring blood pr essur e ............................................................................................................... 5 \n1.2 Diagnosing h yper tension ................................................................................................................ 7 \n1.3 Assessing car diovascular risk and tar get or gan damage ............................................................ 9 \n1.4 Treating and monit oring h yper tension .......................................................................................... 10 \n1.5 Identifying who t o refer for same-da y specialist r eview ............................................................. 24 \nTerms used in t his guideline ................................................................................................................. 25 \nRecommendations f or resear ch ................................................................................................ 27 \nKey recommendations f or resear ch .................................................................................................... 27 \nOther r ecommendations f or resear ch ................................................................................................. 29 \nRationale and impact .................................................................................................................. 31 \nDiagnosing h yper tension ...................................................................................................................... 31 \nRelaxation t herapies ............................................................................................................................. 33 \nStarting antih yper tensiv e drug tr eatment .......................................................................................... 34 \nMonit oring tr eatment and blood pr essur e tar gets ............................................................................. 36 \nChoosing antih yper tensiv e drug tr eatment f or people wit h car diovascular disease ..................... 41 \nStep 1 tr eatment .................................................................................................................................... 42 \nStep 2 and 3 tr eatment ......................................................................................................................... 43 \nStep 4 tr eatment ................................................................................................................................... 44 \nIdentifying who t o refer for same-da y specialist r eview ................................................................... 46", "people wit h ast hma. The y therefore recommended t hat SABA alone should not be used in \npeople wit h a diagnosis of ast hma. \nThe pr evious NICE and BTS/SIGN guidelines had r ecommended a number of actions which \nshould be tak en bef ore incr easing tr eatment, and t he committ ee agr eed b y consensus t hat \na FeNO check should also be done as long as t he equipment is a vailable t o do t his. \nHow the r ecommenda tions mig ht affect practice \nThe pr escription of SABA alone has been commonplace, alt hough t his is becoming less so \nbecause of t he publicity ar ound ast hma deat hs. The r ecommendation will r educe it s use \nfurther. The r eplacement t herapies in adult s and childr en ar e mor e expensiv e, but t hey \nshould pr oduce clinical benefit s and cost sa vings t hrough a r eduction in e xacerbations. \nReturn t o recommendations \nDigital inhaler s \nRecommendation 1 .6.10 \nWhy the c ommi ttee made the r ecommenda tion \nThe committ ee look ed at e vidence comparing t he use of digital smar t inhalers wit h usual \ncare and wit h digital inhalers wit h the feedback utility swit ched off . The trials included \nboth childr en and adult s wit h ast hma, and a v ariety of types of inhaler . The e vidence Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 50 of\n64 showed impr ovement in adher ence t o treatment wit h digital inhalers, but t his did not r esult \nin significant impr ovement in measur es of ast hma contr ol. In addition, t here was an \nunexplained incr ease in hospital admissions among people using digital inhalers when \ncompar ed wit h usual car e. The par ticipant s in t he contributing trials v aried considerably in \nterms of baseline adher ence and ast hma contr ol, and benefit was generally mor e likely in \nthe studies of people wit h poor er baseline v alues. \nDigital inhalers ar e mor e expensiv e than con ventional de vices, par tly because of t he \ndevice it self and par tly because of t he set -up and monit oring r equir ement s. The \ncommitt ee concluded t hat digital inhalers ar e not a cost -effectiv e option f or routine use in \nasthma. Ho wever, they are pot entially v aluable in select ed people wit h ast hma, f or \nexample t hose in whom t he need f or biologic t herap y is being consider ed and t here is a \nneed t o confirm good adher ence. Further r esear ch is needed t o identify mor e precisely t he \npeople and t he cir cumstances in which t hey might be used . \nHow the r ecommenda tion mig ht affect practice \nDigital inhalers ar e not r ecommended f or routine use in t he NHS, and t his is in line wit h \ncurrent practice. \nReturn t o recommendations \nMedicines f or the ini tial manag emen t of newly \ndiagnose d asthma in pe ople ag ed 12 and o ver \nRecommendations 1 .7.1 and 1 .7.2 \nWhy the c ommi ttee made the r ecommenda tions"], "eval_score_GPT4": "1", "eval_feedback_GPT4": "Feedback: The response provided does not answer the question about the type of sphygmomanometers that have replaced mercury-based sphygmomanometers. Instead, it discusses the context of asthma management guidelines, which is unrelated to the question. The response does not mention electronic sphygmomanometers, which is the correct answer according to the reference answer. Therefore, the response is completely incorrect and not factual in relation to the question asked."}, {"question": "What type of medication alone should not be used in people with asthma?", "generated_answer": "Short-acting beta 2 agonists (SABAs) should not be used alone in people with asthma. According to the context, it is recommended to prescribe a low-dose ICS/formoterol combination inhaler used as needed (as-needed AIR therapy) for people with confirmed asthma who are currently using a short-acting beta 2 agonist (SABA) only.", "true_answer": "SABA (short-acting beta 2 agonist) alone should not be used in people with asthma.", "relevant_docs": ["and childr en. These ma y include: \n\u2022 alternativ e diagnoses or comorbidities \n\u2022 suboptimal adher ence (see t he recommendation on adher ence ) \n\u2022 suboptimal inhaler t echnique \n\u2022 smoking (activ e or passiv e), including v aping using e-cigar ettes \n\u2022 occupational e xposur es (see t he recommendation on checking f or possible \noccupational ast hma). \n\u2022 psychosocial f actors (f or example, anxiety and depr ession, r elationships and \nsocial netw orks) Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 16 of\n64 \u2022 seasonal f actors \n\u2022 environmental f actors (f or example, air pollution, indoor mould e xposur e). \n[NICE 2017 , BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n1.6.2 If possible, check t he fractional e xhaled nitric o xide (F eNO) le vel when ast hma is \nuncontr olled. If it is raised t his ma y indicat e poor adher ence t o treatment or t he \nneed f or an incr eased dose of inhaled cor ticost eroid (ICS). [BTS/NICE/SIGN \n202 4] \n1.6.3 Do not pr escribe shor t-acting beta 2 agonist s to people of an y age wit h ast hma \nwithout a concomitant pr escription of an ICS. [BTS/NICE/SIGN 202 4] \n1.6.4 After star ting or adjusting medicines f or ast hma, r eview t he response t o \ntreatment in 8 t o 12 w eeks (see t he recommendations on monit oring ast hma \ncontr ol). [NICE 2017 , amended BTS/NICE/SIGN 202 4] \nFor a shor t explanation of wh y the committ ee made t hese 202 4 recommendations \nand ho w they might aff ect practice, see t he rationale and impact section on principles \nof pharmacological tr eatment . \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview  P: \ndrug classes f or initial ast hma management . \nInhaler s \n1.6.5 Base t he choice of inhaler(s) f or ast hma on: \n\u2022 an assessment of corr ect t echnique \n\u2022 the pr eference of t he person r eceiving t he tr eatment \n\u2022 the lo west en vironmental impact among suitable de vices \n\u2022 the pr esence of an int egral dose count er. \nA spacer should usually be pr escribed f or use wit h a met ered dose inhaler , Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 17 of\n64 particularly in childr en. See t he patient decision aid on ast hma inhalers and \nclimat e change . [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n1.6.6 Give people wit h ast hma inf ormation on t heir inhaler tr eatment s. This should \ninclude t he medicines t hey contain, ho w they work, when t hey should be tak en \nand t he corr ect t echnique t o use f or each de vice. [BTS/SIGN 2019 , amended \nBTS/NICE/SIGN 202 4] \n1.6.7 Obser ve the person using t heir inhaler de vice (and spacer if used) t o check t hey \ncan use it pr operly:", "blood eosinophil count . If eit her of t hese is raised, r efer to a specialist in \nasthma car e. \n\u2022 If neit her F eNO or eosinophil count is raised, consider a trial of eit her a \nleukotriene r ecept or antagonist  (LTRA) or a long-acting muscarinic r ecept or \nantagonist  (LAMA) used in addition t o moderat e-dose MART . Give the \nmedicine f or a trial period of 8 t o 12 w eeks unless t here are side eff ects. At \nthe end of t he trial: \n\uff0d if ast hma is contr olled, continue t he tr eatment \n\uff0d if contr ol has impr oved but is still inadequat e, continue t he tr eatment and \nstart a trial of t he ot her medicine (L TRA or L AMA) Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 20 of\n64 \u2022 if contr ol has not impr oved, st op the LTRA or L AMA and star t a trial of t he \nalternativ e medicine (L TRA or L AMA). [BTS/NICE/SIGN 202 4] \nNovember 202 4: Follow the MHRA saf ety advice on t he risk of \nneuropsy chiatric r eactions in people taking mont elukast . \n1.7.6 Refer people t o a specialist in ast hma car e when ast hma is not contr olled despit e \ntreatment wit h moderat e-dose MART , and trials of an L TRA and a L AMA. (See t he \nAccelerat ed Access Collaborativ e consensus pat hway on t he management of \nuncontr olled ast hma in adult s.) [BTS/NICE/SIGN 202 4] \nFor a shor t explanation of wh y the committ ee made t hese r ecommendations and ho w \nthey might aff ect practice, see t he rationale and impact section on medicine \ncombination and sequencing in people aged 12 and o ver. \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview  Q: \ndrug combinations and sequencing f or ast hma management . \nTransf erring pe ople ag ed 12 and o ver fr om other tr eatmen t \npathways \nThese r ecommendations ar e for people wit h uncontr olled ast hma who ar e on t he \ntreatment pat hway recommended b y previous NICE and BTS/SIGN guidelines. \n1.7.7 Change tr eatment f or people wit h confirmed ast hma who ar e curr ently using a \nshor t-acting beta 2 agonist (SABA) only t o a lo w-dose ICS/f ormot erol combination \ninhaler used as needed (as-needed AIR t herap y). [BTS/NICE/SIGN 202 4] \n1.7.8 Consider changing tr eatment t o low-dose MART f or people wit h ast hma t hat is \nnot contr olled on: \n\u2022 regular lo w-dose ICS plus SABA as needed \n\u2022 regular lo w-dose ICS/L ABA ( long-acting beta 2 agonist ) combination inhaler \nplus SABA as needed Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 21 of\n64 \u2022 regular lo w-dose ICS and supplementar y therap y (LTRA) plus SABA as \nneeded. \n\u2022 regular lo w-dose ICS/L ABA combination inhaler and supplementar y therap y"], "eval_score_GPT4": "5", "eval_feedback_GPT4": "The response correctly identifies that short-acting beta 2 agonists (SABAs) should not be used alone in people with asthma, which aligns with the reference answer. Additionally, the response provides extra factual information regarding the recommendation of a low-dose ICS/formoterol combination inhaler as an alternative, which is accurate and relevant to the context of asthma treatment but not required by the instruction. The response goes beyond the reference answer but does not contradict it. Based on the score rubric, the response is completely correct, accurate, and factual."}, {"question": "What was the effect of regular FeNO monitoring on lung function in children with asthma?", "generated_answer": "The context does not provide information about the effect of regular FeNO monitoring on lung function in children with asthma. It only discusses the diagnostic tests for asthma in children, including FeNO, and the recommended diagnostic sequences, but does not mention the impact of regular FeNO monitoring on lung function.", "true_answer": "Significant improvement in lung function.", "relevant_docs": ["have a raised F eNO le vel. Ho wever, these childr en ma y sho w bronchodilat or reversibility \n(BDR). It was t herefore agr eed t hat it w ould be appr opriat e to use spir ometr y wit h BDR as \na second t est for those wit hout an ele vated FeNO, or as t he first t est in t hose in whom \nFeNO could not be measur ed. Alt hough t his does not f ollow our optimal model e xactly, \nincluding BDR at t his stage is still cost -effectiv e. \nIn childr en wit h a suggestiv e hist ory of ast hma, bot h skin prick t esting f or sensitisation t o \nhouse dust mit e and measur ement of t otal IgE ar e sensitiv e tests, and t he committ ee \nagreed t hat one or t he ot her should be done ne xt. If t he test is negativ e, ast hma is highly Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 45 of\n64 unlik ely and can be ruled out wit hout r esor ting t o bronchial challenge t esting. Alt hough \ntaking blood f or IgE is in vasive, it does ha ve the adv antage t hat an eosinophil count could \nalso be obtained, and if t his is abo ve 0.5 x 109 \nper litr e, it w ould suppor t a diagnosis of \nasthma. \nThe committ ee w ere awar e that t here can be dela ys in obtaining spir ometr y, FeNO \nmeasur ement s or skin prick t esting, and t hat it ma y not be possible t o get blood samples \nfrom some childr en. It is hoped t hat access t o these t ests will impr ove. But if t he tests are \nnot a vailable or t here is a significant dela y in obtaining t hem, t he committ ee agr eed it \nwould be r easonable t o use PEF v ariability as a substitut e rule-in t est. \nThe best single t est is a br onchial challenge t est, but t hese ar e also not r eadily a vailable \nand cannot be done in primar y car e. If t here is still diagnostic doubt aft er per forming ot her \ntests, the committ ee agr eed t hat a r eferral t o an ast hma specialist should be made f or a \nsecond opinion, including consideration of a challenge t est. \nFurther r esear ch \nAlthough t here is e vidence underpinning each of t he tests included in t he recommended \ndiagnostic sequences f or adult s and f or childr en aged 5 t o 16 y ears, t he committ ee \nackno wledged t hat t he sequences t hemselv es ha ve not been t ested. The clinical and \ncost-effectiv eness of t he recommended diagnostic pr ocess should be f ormally e valuat ed. \nChildr en under 5 \nThe main issue in t his age gr oup is diff erentiating ast hma fr om sympt oms caused b y \nrecurr ent viral inf ections. The committ ee w ere awar e of e vidence out side t he review of \ndiagnostic t ests sho wing t hat ast hma is mor e likely than r ecurr ent viral wheez e when t he \nepisodes ar e frequent or se vere, when t hey occur in t he absence of ot her signs of viral \nillness and when t he child sho ws ot her e vidence of at opy. On t his basis, t hey agr eed t hat", "corticost eroids wit hin a self -management pr ogramme in childr en and y oung people wit h \nasthma and r emoved a r ecommendation. A new r ecommendation on self -management in \nchildr en and y oung people was made. This r ecommendation is mark ed [2020 , amended \nBTS/NICE/SIGN 202 4]. \nBTS ISBN: 9 78-1-917 619-01-1 \nNICE ISBN: 9 78-1-47 31-6612- 7 \nSIGN ISBN: 9 78-1-909103-92-4 Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 64 of\n64"], "eval_score_GPT4": "1", "eval_feedback_GPT4": "Feedback: The response does not provide a direct answer to the question regarding the effect of regular FeNO monitoring on lung function in children with asthma. Instead, it states that the context does not provide this information and discusses the diagnostic tests for asthma, including FeNO. This does not align with the reference answer, which clearly states that there was a \"Significant improvement in lung function.\" Therefore, the response is completely incorrect as it fails to mention any effect, let alone the improvement noted in the reference answer."}, {"question": "At what age should children with asthma be referred to a specialist if their asthma is not controlled on moderate-dose treatment?", "generated_answer": "According to the context, if a child is unable to perform objective tests when they are aged 5, and their asthma is not responding to treatment, they should be referred to a specialist respiratory paediatrician.", "true_answer": "5 to 11 years old.", "relevant_docs": ["\u2022 evidence r eview  K: diagnostic accuracy of combination of t ests. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 13 of\n64 1.3 D iagnosing asthma in childr en under 5 \nDiagnosis is har d in t his age gr oup because it is difficult t o do t he tests and t here are no \ngood r eference standar ds. \n1.3.1 For childr en under 5 wit h suspect ed ast hma, tr eat wit h inhaled cor ticost eroids in \nline wit h the recommendations on medicines f or initial management in childr en \nunder  5, and r eview t he child on a r egular basis. If t hey still ha ve sympt oms when \nthey reach 5 y ears, att empt objectiv e tests (see t he section on objectiv e tests for \ndiagnosing ast hma in adult s, young people and childr en aged 5 t o 16). [NICE \n2017] \n1.3.2 If a child is unable t o per form objectiv e tests when t hey are aged 5: \n\u2022 try doing t he tests again e very 6 to 12 mont hs until satisf actory result s are \nobtained \n\u2022 refer for specialist assessment if t he child's ast hma is not r esponding t o \ntreatment. [NICE 2017 , BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n1.3.3 Refer to a specialist r espirat ory paediatrician an y preschool child wit h an \nadmission t o hospital, or 2 or mor e admissions t o an emer gency depar tment, wit h \nwheez e in a 12-mont h period. [BTS/NICE/SIGN 202 4] \n1.4 D iagnosing oc cupa tional asthma \nSee t he BTS clinical stat ement on occupational ast hma. \n1.4.1 In people wit h adult -onset ast hma, poorly contr olled established ast hma, or \nreappearance of childhood ast hma, check f or a possible occupational component \nby asking: \n\u2022 Are sympt oms t he same, bett er or w orse on da ys awa y from w ork? \n\u2022 Are sympt oms t he same, bett er or w orse when on holida y (time awa y from \nwork, longer t han usual br eaks, at w eekends or betw een shift s)? Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 14 of\n64 Make sur e all answ ers ar e recorded f or lat er review . [NICE 2017 , BTS/SIGN \n2019 , amended BTS/NICE/SIGN 202 4] \n1.4.2 Refer people wit h suspect ed occupational ast hma t o an occupational ast hma \nspecialist. [NICE 2017] \n1.5 M onitoring asthma c ontrol \n1.5.1 Monit or asthma contr ol at every review . In addition t o asking about sympt oms, \ncheck: \n\u2022 time off w ork or school due t o ast hma \n\u2022 amount of r eliever inhaler used, including a check of t he pr escription r ecord \n\u2022 number of courses of oral cor ticost eroids \n\u2022 any admissions t o hospital or att endance at an emer gency depar tment due \nto ast hma. \nIf contr ol is suboptimal, see recommendation 1 .6.1 in t he section on principles \nof pharmacological tr eatment . [BTS/NICE/SIGN 202 4]", "Return t o recommendations \nSelf-manag emen t \nRecommendation 1 .14.5 \nWhy the c ommi ttee made the r ecommenda tion \nThe e vidence f or childr en and y oung people f ound t hat incr easing t he dose of ICS when \nasthma contr ol det eriorat es did not r esult in an y benefit s or harms compar ed wit h the \nusual dose in t erms of r educing subsequent ast hma e xacerbations. It was limit ed to only 1 \nstudy wit h a small number of par ticipant s who had a personalised action plan. The \ncommitt ee also look ed at studies in adult s, but t hey agr eed t hat t he evidence was not \napplicable because of t he high a verage age of par ticipant s. \nThe committ ee discussed t he impor tance of a personalised action plan t o guide childr en \nand y oung people if t heir ast hma w orsens and t o reassur e them t hat t hey are in contr ol of \ntheir tr eatment. Childr en and y oung people who find t hat incr easing t heir dose of ICS is \nhelpful when t heir ast hma contr ol worsens should be able t o continue t o do t his as an \nagreed strat egy in t heir action plan. Ho wever, based on t heir e xperience, t he committ ee \nmembers agr eed t hat it is impor tant t o review t he child or y oung person's self -\nmanagement plan if t heir ast hma contr ol is det eriorating. R eviews in volve checking curr ent \nmedicines and inhaler t echnique, discussing an y factors t hat ma y be triggering sympt oms, \ndiscussing adher ence and education needs, and r eviewing t heir action plan. The y should \nbe carried out as needed, in addition t o annual r eview . \nThe committ ee discussed t he impor tance of an individualised appr oach f or childr en and \nyoung people, because t hey have varied and changing suppor t needs at diff erent ages. \nStudies ha ve sho wn that most child ast hma deat hs in volve childr en who ha ve frequent but \nmild sympt oms t hat ar e not r esponding t o management in t heir personalised action plan. \nThis r ecommendation should help t o ensur e that t hese childr en and y oung people r eceiv e \nthe suppor t that t hey need if t hey star t to have problems wit h their ast hma contr ol. Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 59 of\n64 The committ ee agr eed t hat fur ther r esear ch is needed t o giv e clear er guidance on \nincreasing t he dose of ICS in childr en and y oung people wit hin a self -management \nprogramme. The y made a r esear ch recommendation on incr easing t he dose of ICS wit hin a \npersonalised self -management pr ogramme f or childr en and y oung people  to promot e \nfurther r esear ch and inf orm futur e practice. \nHow the r ecommenda tion mig ht affect practice \nThe r ecommendation will lead t o an incr ease in t he review of self -management \nprogrammes f or childr en and y oung people and r educe t he variation in curr ent practice f or"], "eval_score_GPT4": "3", "eval_feedback_GPT4": "The response provided does not specify an age range but rather a condition under which children should be referred to a specialist. While it is related to the management of asthma in children, it does not answer the specific question about the age at which children should be referred if their asthma is not controlled on moderate-dose treatment. The reference answer clearly states \"5 to 11 years old,\" which is a direct and specific age range. The response given is somewhat related but lacks the precision and directness of the reference answer. Therefore, it is somewhat correct but not entirely accurate or factual in the context of the question asked."}, {"question": "What is the blood pressure threshold for accelerated hypertension?", "generated_answer": "According to the context, accelerated hypertension is defined as a severe increase in blood pressure to 180/120 mmHg or higher (and often over 220/120 mmHg) with signs of retinal hemorrhage and/or papilloedema (swelling of the optic nerve).", "true_answer": "180/120 mmHg or higher (and often over 220/120 mmHg).", "relevant_docs": ["\u2022 information about what t o do if t hey are not achie ving t heir tar get blood \npressur e. Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 15 of\n52 Be awar e that t he corr esponding measur ement s for HBPM ar e 5 mmHg lo wer \nthan f or clinic measur ement s (see recommendation  1.2.8 for diagnostic \nthresholds ). [2019] \n1.4.20 For adult s wit h hyper tension aged under  80, reduce clinic blood pr essur e to \nbelow 140/90  mmHg and ensur e that it is maintained belo w that le vel. See also \ntable 1 f or guidance on clinic blood pr essur e tar gets for people aged under 80 \nwith type 1 diabet es or se vere chr onic kidne y disease . [2019 , amended 2022] \n1.4.21 For adult s wit h hyper tension aged 80  and o ver, reduce clinic blood pr essur e to \nbelow 150/90  mmHg and ensur e that it is maintained belo w that le vel. Use clinical \njudgement f or people wit h frailty or multimorbidity (see NICE's guideline on \nmultimorbidity ). See also table 2 f or guidance on clinic blood pr essur e tar gets for \npeople aged 80 and o ver wit h type 1 diabet es or se vere chr onic kidne y disease . \n[2019 , amended 2022] \n1.4.22 When using ABPM or HBPM t o monit or the response t o treatment in adult s wit h \nhyper tension, use t he average blood pr essur e level tak en during t he person's \nusual waking hours (see recommendations  1.2.6 and 1 .2.7). Reduce blood \npressur e and ensur e that it is maintained: \n\u2022 below 135/85  mmHg f or adult s aged under  80 \n\u2022 below 145/85  mmHg f or adult s aged 80  and o ver. \nUse clinical judgement f or people wit h frailty or multimorbidity (see also \nNICE's guideline on multimorbidity). [2019 , amended 2022] \nFor a shor t explanation of wh y the committ ee made t he 2019 r ecommendations and \nhow they might aff ect practice, see t he rationale and impact section on monit oring \ntreatment and blood pr essur e tar gets for people wit hout car diovascular disease . \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview B: \nmonit oring t he response t o treatment . \n1.4.23 Use t he same blood pr essur e tar gets for people wit h and wit hout car diovascular Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 16 of\n52 disease. [2022] \nFor a shor t explanation of wh y the committ ee made t he recommendation on blood \npressur e tar gets for people wit h car diovascular disease and ho w this might aff ect \npractice, see t he rationale and impact section on monit oring tr eatment and blood \npressur e tar gets for people wit h car diovascular disease . \nFull details of t he evidence and t he committ ee's discussion ar e in t he evidence r eview \nJ: blood pr essur e tar gets.", "conditions#notice-of -right s).Page 2 4 of\n52 Terms use d in this guideline \nThis section defines t erms t hat ha ve been used in a par ticular wa y for this guideline. F or \nother definitions see t he NICE glossar y. \nAccelerated hyper tension \nA severe incr ease in blood pr essur e to 180/120  mmHg or higher (and oft en over 220/\n120 mmHg) wit h signs of r etinal haemorrhage and/or papilloedema (sw elling of t he optic \nnerve). It is usually associat ed wit h new or pr ogressiv e tar get or gan damage and is also \nknown as malignant h yper tension. \nEstab lishe d cardiovascular dise ase \nMedical hist ory of ischaemic hear t disease, cer ebrovascular disease, peripheral v ascular \ndisease, aor tic aneur ysm or hear t failure. Car diovascular disease is a general t erm f or \nconditions aff ecting t he hear t or blood v essels. It is usually associat ed wit h a build-up of \nfatty deposit s inside t he ar teries (at heroscler osis) and an incr eased risk of blood clot s. It \ncan also be associat ed wit h damage t o arteries in or gans such as t he brain, hear t, kidne ys \nand e yes through deposition of glassy mat erial wit hin the ar tery walls (ar terioscler osis). \nCardiovascular disease is 1 of t he main causes of deat h and disability in t he UK, but it can \noften lar gely be pr evented by leading a healt hy lifestyle. \nMasked hyper tension \nClinic blood pr essur e measur ement s are normal (less t han 140/90  mmHg), but blood \npressur e measur ement s are higher when tak en out side t he clinic using a verage da ytime \nambulat ory blood pr essur e monit oring (ABPM) or a verage home blood pr essur e monit oring \n(HBPM) blood pr essur e measur ement s. \nPersisten t hyper tension \nHigh blood pr essur e at r epeat ed clinical encount ers. \nStage 1 hyper tension \nClinic blood pr essur e ranging fr om 140/90  mmHg t o 159/99  mmHg and subsequent ABPM Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 25 of\n52 daytime a verage or HBPM a verage blood pr essur e ranging fr om 135/85  mmHg t o 149/\n94 mmHg. \nStage 2 hyper tension \nClinic blood pr essur e of 160/100  mmHg or higher but less t han 180/120  mmHg and \nsubsequent ABPM da ytime a verage or HBPM a verage blood pr essur e of 150/95  mmHg or \nhigher . \nStage 3 or se vere hyper tension \nClinic syst olic blood pr essur e of 180  mmHg or higher or clinic diast olic blood pr essur e of \n120 mmHg or higher . \nTarget organ damag e \nDamage t o organs such as t he hear t, brain, kidne ys and e yes. Examples ar e left v entricular \nhyper trophy, chronic kidne y disease, h yper tensiv e retinopat hy or incr eased urine \nalbumin:cr eatinine ratio. \nWhite-coat effect \nA discr epancy of mor e than 20/10  mmHg betw een clinic and a verage da ytime ABPM or"], "eval_score_GPT4": "5", "eval_feedback_GPT4": "Feedback: The response provided is completely correct, accurate, and factual. It matches the reference answer by stating the blood pressure threshold for accelerated hypertension as 180/120 mmHg or higher. Additionally, it includes the context of often being over 220/120 mmHg and mentions associated symptoms, which aligns with the detailed nature of the reference answer."}, {"question": "What medications are advised for use during pregnancy for asthma control?", "generated_answer": "According to the context, the following medications are advised for use during pregnancy for asthma control:\n\n1. Short-acting and long-acting beta2 agonists\n2. Inhaled corticosteroids\n3. Oral theophyllines\n\nThese medications are recommended for use during pregnancy, as stated in section 1.12.3 of the context.", "true_answer": "Short-acting and long-acting beta 2 agonists, inhaled corticosteroids, and oral theophyllines.", "relevant_docs": ["good contr ol of ast hma during pr egnancy and of continuing ast hma medicines t o \navoid pr oblems f or themselv es and t heir bab y. [BTS/SIGN 2019] \n1.12.2 Advise an yone who is pr egnant and who smok es about t he dangers f or \nthemselv es and t heir babies and giv e appr opriat e suppor t to stop smoking. See \nthe NICE guideline on t obacco  for mor e information. [BTS/SIGN 2019] \n1.12.3 Advise using t he following medicines as normal during pr egnancy: \n\u2022 shor t-acting and long-acting beta 2 agonist s \n\u2022 inhaled cor ticost eroids \n\u2022 oral t heoph yllines. [BTS/SIGN 2019] \n1.12.4 Offer oral cor ticost eroids during pr egnancy if needed t o treat e xacerbations of \nasthma. Advise t hat t he benefit s of tr eatment wit h oral cor ticost eroids outw eigh \nthe risks. [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n1.12.5 If leuk otriene r ecept or antagonist s or long-acting muscarinic r ecept or antagonist s \nare needed t o achie ve ast hma contr ol, they should not be st opped during \npregnancy . [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \nBreastfeeding \n1.12.6 Use medicines as normal when br eastf eeding in line wit h recommendations in t he \nBNF. [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 28 of\n64 1.13 A sthma in ado lescents \nFor guidance on transitioning t o adult ser vices, see t he NICE guideline on transition fr om \nchildr en's t o adult s' ser vices f or young people using healt h or social car e ser vices  and t he \nScottish Parliament Inf ormation Centr e briefing on transitions of y oung people wit h ser vice \nand car e needs betw een child and adult ser vices in Scot land. \n1.13.1 Discuss futur e car eer choices wit h adolescent s wit h ast hma and highlight \noccupations t hat might incr ease susceptibility t o work-related ast hma sympt oms. \n[BTS/SIGN 2019] \n1.13.2 Ask adolescent s wit h ast hma if t hey vape or smok e and encourage t hem t o stop. \nIf they smok e, giv e them advice and signpost t hem t o local NHS st op smoking \nservices. [BTS/SIGN 2019 , amended BTS/NICE/SIGN 202 4] \n1.13.3 Ask about f actors t hat ma y affect a person's use of t heir inhaler de vice in r eal lif e \nsettings, such as school and social situations. [BTS/SIGN 2019] \n1.14 Self -manag emen t \n1.14.1 For adult s, young people and childr en aged 5 and o ver wit h a diagnosis of ast hma \n(and t heir f amilies or car ers, if appr opriat e): \n\u2022 Offer an ast hma self -management pr ogramme, comprising a document ed \npersonalised action plan and education. In adult s, they ma y be based on \nsympt oms or peak e xpirat ory flow (or bot h); sympt om-based plans ar e \nusually pr eferred for childr en. \n\u2022 Explain t hat t here are things t hat can trigger ast hma sympt oms and", "best), and minimal side eff ects from tr eatment. \nAtopic disor der \nAtopic disor ders ar e aller gic conditions including aller gic rhinitis (ha y fever), at opic \ndermatitis ( eczema), aller gic ast hma and ot her specific and non-specific aller gic \nconditions such as f ood aller gies. \nBronchial challeng e test \nA test t o measur e airway responsiv eness (br onchial r esponsiv eness). It is per formed b y \ngiving small incr ement s of a br onchoconstrict or (most commonly met hacholine) and \nmeasuring t he FEV 1 after each dose until it f alls b y a pr edet ermined amount (usually 20% \nfrom baseline). \nBronchial h yperr esponsi veness \nA measur e of ho w easily br onchospasm can be induced in t he air ways. It is measur ed \nusing a br onchial challenge t est. \nBronchodila tor r eversibility \nA measur e of t he ability t o reverse obstruction in t he air ways using medicines t hat widen Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 33 of\n64 the air ways (br onchodilat ors). \nEosinop hil c ount \nThe number of eosinophils (a type of whit e blood cell) measur ed in a blood sample. Their \nlevels ar e raised in ast hma and ot her aller gic diseases, and less commonly wit h malignant \ndiseases, parasit e infections, r eactions t o some medicines, and a small number of rar e \ndiseases. \nFeNO test \nA test t hat measur es the amount of nitric o xide (NO) pr esent on e xhalation, usually \nexpressed in par ts per billion. \nFEV1 \nThe amount of air t hat can be f orcibly e xhaled fr om t he lungs in one second (f orced \nexpirat ory volume in one second). \nLeuk otriene r eceptor an tagonist \nA type of oral medicine t hat blocks cyst einyl leuk otrienes, used in t he tr eatment of ast hma \nand seasonal aller gies. Also kno wn as leuk otriene modifiers. \nLong-ac ting be ta2 agonist \nA long-acting medicine t hat act s on beta-r ecept ors in t he air way to relax air way smoot h \nmuscle and r elieve sympt oms of ast hma. \nLong-ac ting m uscarinic r eceptor an tagonist \nA long-acting medicine t hat act s on muscarinic r ecept ors in t he air way to relax air way \nsmoot h muscle and r elieve sympt oms of ast hma. \nMaintenanc e and r eliever ther apy (MART) \nA form of combined ICS plus f ormot erol treatment in which a single inhaler containing ICS Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 34 of\n64 and f ormot erol is used f or daily maint enance t herap y and t he relief of sympt oms as \nneeded. The t erms lo w-dose MART and moderat e-dose MART r efer to the dosage of t he \nmaint enance component of MART . People using MART do not normally need a SABA."], "eval_score_GPT4": "5", "eval_feedback_GPT4": "The response provided lists the same medications as the reference answer: short-acting and long-acting beta2 agonists, inhaled corticosteroids, and oral theophyllines. This indicates that the response is correct and factual. Additionally, the response includes a reference to a specific section of the context, which is not required but shows an attempt to cite a source, although \"the context\" is not a clear source. However, since the rubric only assesses correctness, accuracy, and factuality, the additional citation does not influence the score. The response accurately reflects the reference answer and therefore meets the criteria for a score of 5."}, {"question": "How long should one wait before considering a further treatment reduction when decreasing maintenance therapy for asthma?", "generated_answer": "According to the context, when changing from low- or moderate-dose ICS (or ICS/LABA combination inhaler) plus supplement therapy to maintenance therapy (MART), the committee recommends considering whether to stop or continue the supplement therapy based on the degree of benefit achieved when first introduced. There is no specific time frame mentioned for waiting before considering a further treatment reduction.", "true_answer": "Allow at least 8 to 12 weeks before considering a further treatment reduction.", "relevant_docs": ["directly in 2 small studies. Alt hough t he comparison sho wed a r eduction in e xacerbations \nwith a L AMA compar ed wit h an L TRA, t he committ ee did not ha ve much confidence in t he \nresult because of t he small study population. The y not ed that it w ould be simpler t o add \nan LTRA t han a L AMA because t he latt er would in volve needing t o teach t he person wit h \nasthma ho w to use an additional inhaler de vice, and t he need f or 2 inhalers is also less \nenvironmentally desirable. An L TRA is also cheaper , but t here is a risk of significant side \neffects, par ticularly neur opsy chiatric disturbances. It was agr eed t hat t here was no \nconvincing r eason t o recommend one option o ver the ot her and t hat t he person wit h \nasthma should decide which should be tried first aft er a discussion of t he pot ential \nbenefit s and harms. \nIf these medicines ha ve been tried and t he person's ast hma continues t o be inadequat ely \ncontr olled, fur ther tr eatment is a vailable using a v ariety of biologic agent s. Use of t hese \nfalls out side t he scope of t his guideline and r equir es specialist assessment. The committ ee \ntherefore recommended t hat a r eferral should be made at t his stage. \nHow the r ecommenda tions mig ht affect practice \nThe r ecommendations f or incr easing tr eatment ar e diff erent fr om curr ent standar d \npractice, but t hey apply t o people wit h a new diagnosis of ast hma. P eople wit h an e xisting \ndiagnosis of ast hma who ar e stable on t heir curr ent t herap y do not ha ve to swit ch \ntreatment. P eople on curr ent pat hways who need an incr ease in tr eatment will be swit ched \nto MART , but t his is one of t he curr ent options. Ther e should t herefore not be significant \ndisruption t o ast hma car e. The new tr eatment st eps ar e cost -effectiv e for the NHS and in \nparticular will r educe t he number of e xacerbations r equiring tr eatment and t he number of \nhospital admissions f or ast hma. \nReturn t o recommendations Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 54 of\n64 Transf erring pe ople ag ed 12 and o ver fr om other \ntreatmen t pathways \nRecommendations 1 .7.7 to 1.7.11 \nWhy the c ommi ttee made the r ecommenda tions \nThe tr eatment pat hway recommended in t his guideline updat e for people aged 12 and o ver \nrelies on using MART wit h incr easing dose of r egular ICS/f ormot erol, depending on \nresponse t o treatment. This is a diff erent strat egy fr om t hat r ecommended b y previous \nguidelines (NICE and BTS/SIGN) and man y people will be on tr eatment t hat is not par t of \nthis new pat hway. The committ ee recognised t hat t his will cause a pr oblem f or these \npeople when t heir ast hma is not contr olled. The y therefore discussed and agr eed ho w", "plus SABA as needed Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 21 of\n64 \u2022 regular lo w-dose ICS and supplementar y therap y (LTRA) plus SABA as \nneeded. \n\u2022 regular lo w-dose ICS/L ABA combination inhaler and supplementar y therap y \n(LTRA) plus SABA as needed. [BTS/NICE/SIGN 202 4] \n1.7.9 Consider changing tr eatment t o moderat e-dose MART f or people wit h ast hma \nthat is not contr olled on: \n\u2022 regular moderat e-dose ICS plus SABA as needed \n\u2022 regular moderat e-dose ICS/L ABA combination inhaler plus SABA as needed \n\u2022 regular moderat e-dose ICS and supplementar y therap y (LTRA or L AMA, or \nboth) plus SABA as needed \n\u2022 regular moderat e-dose ICS/L ABA combination inhaler and supplementar y \ntherap y (LTRA or L AMA, or bot h) plus SABA as needed. [BTS/NICE/SIGN \n202 4] \n1.7.10 When changing fr om lo w- or moderat e-dose ICS ( or ICS/L ABA combination \ninhaler) plus supplementar y therap y to MART , consider whet her t o stop or \ncontinue t he supplementar y therap y based on t he degr ee of benefit achie ved \nwhen first intr oduced. [BTS/NICE/SIGN 202 4] \n1.7.11 Refer people wit h ast hma t hat is not contr olled on tr eatment containing a high \ndose of ICS t o a specialist in ast hma car e. [BTS/NICE/SIGN 202 4] \nFor a shor t explanation of wh y the committ ee made t hese r ecommendations and ho w \nthey might aff ect practice, see t he rationale and impact section on transf erring people \naged 12 and o ver from ot her tr eatment pat hways. \nFull details of t he evidence and t he committ ee's discussion ar e in evidence r eview  P: \ndrug classes f or initial ast hma management and evidence r eview Q: drug \ncombinations and sequencing f or ast hma management . \n1.8 P harmac ological manag emen t in childr en ag ed 5 Asthma: diagnosis, monit oring and chr onic ast hma management (BTS, NICE, SIGN)\n(NG2 45)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 22 of\n64 to 11 \nFor guidance on doses on inhaled cor ticost eroids see inhaled cor ticost eroid doses f or the \nBTS, NICE and SIGN ast hma guideline . \nSee also algorit hm D f or a summar y of t he pharmacological management of ast hma in \nchildr en aged 5 t o 11 y ears. \nInitial manag emen t in childr en ag ed 5 to 11 \n1.8.1 Offer a twice-daily paediatric lo w-dose inhaled cor ticost eroid (ICS), wit h a shor t-\nacting beta 2 agonist (SABA) as needed, as initial tr eatment f or childr en aged 5 t o \n11 years wit h newly diagnosed ast hma. [BTS/NICE/SIGN 202 4] \nFor a shor t explanation of wh y the committ ee made t his recommendation and ho w it \nmight aff ect practice, see t he rationale and impact section on medicines f or initial \nmanagement in childr en aged 5 t o 11."], "eval_score_GPT4": "2", "eval_feedback_GPT4": "Feedback: The response does not provide a specific time frame for waiting before considering a further treatment reduction, which is a key piece of information present in the reference answer. The reference answer clearly states that one should wait at least 8 to 12 weeks before considering further treatment reduction, which is a factual detail necessary for the response to be considered accurate. Therefore, the response is mostly incorrect and not factual as it fails to mention the specific time frame that is crucial for the question asked."}, {"question": "What is considered a significant drop in systolic blood pressure for postural hypotension?", "generated_answer": "According to the context, a significant drop in systolic blood pressure for postural hypotension is considered to be a fall by 20 mmHg or more.", "true_answer": "A drop of 20 mmHg or more.", "relevant_docs": ["\u2022 measur e blood pr essur e again aft er the person has been standing f or at least \n1 minut e. [2004 , amended 2023] \n1.1.6 If the person's syst olic blood pr essur e falls b y 20 mmHg or mor e, or t heir diast olic \nblood pr essur e falls b y 10 mmHg or mor e, aft er the person has been standing f or \nat least 1 minut e: \n\u2022 consider lik ely causes, including r eviewing t heir curr ent medication \n\u2022 manage appr opriat ely (f or example, f or advice on pr eventing f alls in older \npeople, see NICE's guideline on f alls in older people: assessing risk and \nprevention ) \n\u2022 measur e subsequent blood pr essur es wit h the person standing \n\u2022 consider r eferral t o specialist car e if sympt oms of postural h ypot ension \npersist despit e addr essing lik ely causes. [2004 , amended 2023] \n1.1.7 If the blood pr essur e drop is less t han t he thresholds in r ecommendation 1 .1.6 \ndespit e suggestiv e sympt oms and t he baseline measur ement was pr eviously Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 6 of\n52 taken fr om a seat ed position, r epeat t he measur ement s this time star ting wit h the \nperson lying on t heir back. [2023] \n1.1.8 Consider r eferring t he person f or fur ther specialist assessment if blood pr essur e \nmeasur ement s do not confirm postural h ypot ension despit e suggestiv e \nsympt oms. [2023] \n1.2 D iagnosing h yper tension \n1.2.1 When considering a diagnosis of h yper tension, measur e blood pr essur e in bot h \narms: \n\u2022 If the diff erence in r eadings betw een arms is mor e than 15  mmHg, r epeat t he \nmeasur ement s. \n\u2022 If the diff erence in r eadings betw een arms r emains mor e than 15  mmHg on \nthe second measur ement, measur e subsequent blood pr essur es in t he arm \nwith the higher r eading. [2019] \n1.2.2 If blood pr essur e measur ed in t he clinic is 140/90  mmHg or higher: \n\u2022 Take a second measur ement during t he consultation. \n\u2022 If the second measur ement is substantially diff erent fr om t he first, tak e a \nthird measur ement. \nRecord the lo wer of t he last 2  measur ement s as t he clinic blood pr essur e. \n[2019] \n1.2.3 If clinic blood pr essur e is betw een 140/90  mmHg and 180/120  mmHg, off er \nambulat ory blood pr essur e monit oring (ABPM) t o confirm t he diagnosis of \nhyper tension. See t he section on identifying who t o refer for people wit h a clinic \nblood pr essur e 180/120  mmHg or higher . [2019] \n1.2.4 If ABPM is unsuitable or t he person is unable t o tolerat e it, off er home blood \npressur e monit oring (HBPM) t o confirm t he diagnosis of h yper tension. [2019] Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 7 of", "140 mmHg in people wit h primar y hyper tension wit hout type  2 diabet es. Alt hough t he \nevidence suggest ed some benefit in r educing mor tality and car diovascular e vents, the \nlower blood pr essur e tar get was associat ed wit h a gr eater risk of harms, such as injur y \nfrom falls and acut e kidne y injur y. The committ ee agr eed t hat t he long-t erm implications of \nthese adv erse e vents were unclear and t hat fur ther r esear ch is needed. \nThis e vidence came fr om t he SPRINT trial, which was a lar ge study under taken in t he US. \nThe committ ee discussed concerns about t he population included in t he study and t he \napplicability t o UK practice of t he met hods used. The study used aut omat ed blood \npressur e devices wit h a time dela y and an isolat ed rest period, which is not common \npractice in t he UK. The committ ee consider ed that t he use of t hese de vices w ould lead t o \nlower blood pr essur e readings t han in r outine UK clinical practice. The y also had concerns \nthat some medicines w ere stopped when blood pr essur e tar gets were achie ved, which \nmay have had an impact on t he result s. The committ ee also discussed concerns about \napplicability of t he population; f or example, t he par ticipant s had high car diovascular risk \nlevels, including man y wit h pre-existing car diovascular disease or r enal impairment, and \nwere already r eceiving tr eatment bef ore the study star ted. These concerns made t he \nevidence difficult t o interpret and use t o inform t he recommendations. F urther details of \nthe committ ee's discussion of t his study is included in evidence r eview D: tar gets. \nEvidence fr om a smaller study also sho wed some benefit of lo wering clinic syst olic blood \npressur e tar gets to 130  mmHg. Ho wever, the committ ee not ed that t he study was based \non people alr eady r eceiving tr eatment and t hat it lack ed inf ormation on adv erse e vents. \nThe committ ee agr eed t hat t here was no e vidence t o suggest t hat blood pr essur e tar gets \nshould be diff erent in people wit h type  2 diabet es. Evidence f or lower tar gets in people \nwith type  2 diabet es was also limit ed, wit h some e vidence t o suggest t hat lo wer blood \npressur e tar gets did not r educe t he rat e of car diovascular e vents. Previous \nrecommendations f or people wit h type  2 diabet es (in NICE's guideline on type  2 diabet es \nin adult s) suggest ed a blood pr essur e tar get belo w 130/80  mmHg in t he pr esence of \ntarget or gan damage such as kidne y, cerebrovascular or e ye disease. The committ ee \nnoted that t he evidence behind t his recommendation was based on 2  small studies in Hyper tension in adult s: diagnosis and management (NG136)\n\u00a9 NICE 202 4. All right s reserved. Subject t o Notice of right s (https://www .nice.or g.uk/t erms-and-\nconditions#notice-of -right s).Page 38 of\n52 people wit hout h yper tension. The y also had concerns about t he relevance of t he study"], "eval_score_GPT4": "5", "eval_feedback_GPT4": "The response provided is completely correct, accurate, and factual. It aligns perfectly with the reference answer, stating that a significant drop in systolic blood pressure for postural hypotension is a fall by 20 mmHg or more, which is the exact information needed to answer the question."}]